Boji Medical Technology Co (300404.SZ) Stock Price

Boji Medical Technology Co., Ltd. generates revenue through comprehensive CRO services for pharmaceutical and medical device development. The company offers preclinical research, clinical trials, data management, biostatistics, and regulatory consulting, primarily serving domestic pharmaceutical companies and research institutions. Their one-stop service model includes drug evaluation, medical device registration, and CDMO services for new drug and device production. The firm's domestic market focus ensures steady demand from local clients seeking regulatory compliance and R&D support. The company's revenue streams are derived from multiple service segments: preclinical studies, clinical research, and technology transfer. These services are tailored to meet the needs of pharmaceutical firms requiring outsourced R&D solutions. CDMO services further enhance their offerings by supporting manufacturing processes alongside development. Domestic clients form the core customer base, leveraging Boji's expertise in navigating China's regulatory landscape for drug and device approvals. Boji Medical Technology's business model centers on providing end-to-end CRO solutions, combining preclinical and clinical research with regulatory support. Their services are designed to accelerate product development cycles for clients, reducing time-to-market for new pharmaceuticals and medical devices. The firm's domestic market strategy aligns with the growing demand for R&D outsourcing within China's healthcare sector.